Generali Asset Management SPA SGR Raises Position in Stryker Corporation $SYK

Key Points

• Generali Asset Management SPA SGR increased its stake in Stryker Corporation by 6.9%, owning a total of 18,484 shares valued at $7,313,000 as of the latest SEC filing.
• Analyst ratings for Stryker show a consensus of "Moderate Buy" with a target price of $431.76, with firms like Wells Fargo raising their price objective from $435.00 to $445.00.
• Stryker recently announced a quarterly dividend of $0.84 per share, representing an annual yield of 0.9%, with a payout ratio of 44.50%.

Generali Asset Management SPA SGR raised its stake in Stryker Corporation (NYSE:SYK - Free Report) by 6.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,484 shares of the medical technology company's stock after purchasing an additional 1,190 shares during the quarter. Generali Asset Management SPA SGR's holdings in Stryker were worth $7,313,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of SYK. Sachetta LLC raised its position in Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock valued at $29,000 after buying an additional 27 shares during the last quarter. Goodman Advisory Group LLC purchased a new stake in shares of Stryker in the first quarter valued at about $32,000. Ridgewood Investments LLC raised its holdings in shares of Stryker by 48.4% in the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company's stock valued at $36,000 after purchasing an additional 30 shares during the last quarter. Ransom Advisory Ltd purchased a new stake in shares of Stryker in the first quarter valued at about $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in Stryker in the 1st quarter valued at about $40,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on SYK. Redburn Partners set a $420.00 price objective on shares of Stryker in a research note on Thursday, September 18th. Rothschild Redb raised Stryker to a "hold" rating in a research report on Thursday, September 18th. BTIG Research raised their target price on Stryker from $407.00 to $408.00 and gave the company a "buy" rating in a research report on Monday. Truist Financial decreased their target price on Stryker from $415.00 to $407.00 and set a "hold" rating for the company in a research report on Wednesday. Finally, Wells Fargo & Company raised their price objective on shares of Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $431.76.

Stryker Price Performance

SYK opened at $369.60 on Thursday. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a market capitalization of $141.30 billion, a price-to-earnings ratio of 48.95, a PEG ratio of 2.67 and a beta of 0.94. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average price of $379.60 and a 200-day moving average price of $378.78.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same period in the previous year, the business earned $2.81 EPS. Stryker's revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker's payout ratio is presently 44.50%.

Insider Transactions at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of Stryker stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares of the company's stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.